Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Business, Policy & Funding » Business News » Palmetto Issues Final LCD for DermTech Pigmented Lesion Assay

Palmetto Issues Final LCD for DermTech Pigmented Lesion Assay

Jan 02, 2020
|
staff reporter

NEW YORK – Dermatology genomics testing company DermTech said on Thursday that Medicare Administrative Contractor Palmetto GBA MolDx has issued a final local coverage determination for the company's Pigmented Lesion Assay (PLA).

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

UK Funds Challenge Trial

The UK is investing £33.6 million into a controversial human SARS-CoV-2 challenge study, according to Reuters.

Watching the Changes

The Guardian reports that the UK COVID genomics consortium is monitoring mutations that are arising within circulating SARS-CoV-2 strains for any that may affect future vaccines.

Max Planck, Nature Strike a Deal

Science reports that Max Planck and Nature have struck a deal for affiliated authors to publish papers that are accessible to the public as well as access Nature-branded journals.

PNAS Papers on Ancient Tibetan Animals, HNSCC Drug Response, More

In PNAS this week: genomic analysis of ancient animals from Tibet, oncoproteins tied to WEE1 kinase enzyme inhibitor response, and more.

What's Popular?

In Business News

  1. CMS Colon Cancer Screening Memo Bodes Well for Assays in Development; Denies Epi ProColon

  2. LumiraDx Gets FDA Emergency Use Authorization for PCR-Based Coronavirus Test

  3. 10x Genomics Acquisitions Point Towards New In Situ Analyisis Platform

    Premium

  4. Coronavirus Testing Specimen Collection Devices From DNA Genotek, Clinical Enterprises Get FDA EUAs

  5. Proteintech Acquires Recombinant Reagent Manufacturer ChromoTek

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.